Neuroscience

Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

Retrieved on: 
Tuesday, February 27, 2024
NERV, CRL, Myenteric plexus, FDA, Food, Biopharmaceutical, Schizophrenia, Roluperidone, Symantec Endpoint Protection, Safety, Patient, Neuroscience, NDA, Pharmaceutical industry

The NDA submission lacks data needed to establish that the change in negative symptoms of schizophrenia with roluperidone treatment was clinically meaningful.

Key Points: 
  • The NDA submission lacks data needed to establish that the change in negative symptoms of schizophrenia with roluperidone treatment was clinically meaningful.
  • The submitted safety database included an inadequate number of subjects exposed to roluperidone at the proposed dose (64 mg) for at least 12 months.
  • To address these deficiencies, the FDA stated that Minerva must submit at least one additional positive, adequate, and well-controlled study to support the safety and effectiveness of roluperidone for the treatment of negative symptoms.
  • “There is a critical need for a treatment for the negative symptoms of schizophrenia.

Red light therapy for neuro/cognitive benefits

Retrieved on: 
Friday, February 23, 2024
Emotion, Neuroscience, Journal of Neuroscience Research, Neuron, Amnesia, Growth, Swelling, TBI, Perception, Attention, Mammal, Circadian rhythm, Diagnosis, PBM, Sunlight, Head, Traumatic brain injury, Stroke, DSM-IV codes, Memory, Light, Immunity, Brain, Anxiety, Randomized controlled trial, Sleep, Radical, Learning, Parkinson's disease, RLT, Oxidative stress, Glucose, Potential, LLLT, Research, Human, LED, BBA, System, Dicarboxylic acid, Inflammation, Neuroprotection, FDA, Sensation, Ageing, Thought, Cell, Brain damage, Nutrient, Patient, Cognition, Dementia, Antioxidant, Medical imaging

There is a simple and practical way – red light therapy to improve your brain function.

Key Points: 
  • There is a simple and practical way – red light therapy to improve your brain function.
  • Red light therapy (RLT), also known as low-level laser therapy (LLLT) or photobiomodulation (PBM), involves exposure to specific wavelengths of visible red and near-infrared light (660-850 nm) to stimulate biological processes in the body.
  • Red light therapy increases mitochondria function to promote balance between free radicals and antioxidants in the body.
  • Studies have highlighted red light therapy has a potential neuroprotective and disease-modifying role in treating Alzheimer's and Parkinson's patients.

Six Years Strong: Founder of Revitalist Kathryn Walker’s Continuous Leadership in Revolutionizing Mental Health Care

Retrieved on: 
Friday, February 23, 2024
Artificial intelligence, AI, Neuroscience, Intelligence, DSM-IV codes, Telehealth, Ketamine, Pain, Trauma Center, Suicidal ideation, Depression, Anxiety, Trauma, Anesthesia, COVID-19, City, Therapy, Patient, Wellness, PTSD, Science, Statistics, Pharmaceutical industry

The COVID-19 pandemic especially, has exacerbated mental health issues, with increased mood disorders, substance use, and suicidal ideation rates.

Key Points: 
  • The COVID-19 pandemic especially, has exacerbated mental health issues, with increased mood disorders, substance use, and suicidal ideation rates.
  • Kate NeuroPsych represents a groundbreaking approach to mental health care — offering 24/7 availability, personalized recommendations, and worldwide access — being designed by scientific leaders who are positively disrupting healthcare delivery at Revitalist and Sama Therapeutics .
  • Looking ahead, Kathryn envisions a future where psychedelics are normalized as essential tools in mental health care.
  • With each milestone she achieves, Kathryn Walker continues to redefine the boundaries of mental health care and inspire hope for a brighter, more compassionate future.

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

Retrieved on: 
Thursday, February 22, 2024
Therapy, PMN, BIO, Neuroscience, Conference

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will present at the 2024 BIO CEO & Investor Conference, taking place in-person in New York, NY on February 26-27, 2024.

Key Points: 
  • CAMBRIDGE, Massachusetts and TORONTO, Ontario, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will present at the 2024 BIO CEO & Investor Conference, taking place in-person in New York, NY on February 26-27, 2024.
  • ProMIS Neurosciences senior management will also conduct one-on-one meetings during the conference.
  • For more information or to schedule a meeting, please visit the conference page here or contact ProMIS Neurosciences Investor Relations.

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates

Retrieved on: 
Thursday, February 22, 2024
Research, NERV, Myenteric plexus, FDA, Physician, Food, File, Schizophrenia, Sale, PDUFA, Roluperidone, Patient, G&A, Neuroscience, NDA, Insurance, Pharmaceutical industry

BURLINGTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • BURLINGTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2023.
  • Research and development (R&D) expense: For the three months ended December 31, 2023 and 2022, R&D expense was $4.7 million and $3.2 million, respectively.
  • For the years ended December 31, 2023 and 2022, R&D expense was $12.7 million and $14.6 million, respectively.
  • Cash Position: Cash, cash equivalents and restricted cash at December 31, 2023, were approximately $41.0 million, as compared to $36.2 million at December 31, 2022.

Alto Neuroscience to Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, March 7, 2024
Biotechnology, Neurology, Mental Health, Health, Pharmaceutical, Neuroscience, Alto

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that company management will participate in the following upcoming investor conferences:

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that company management will participate in the following upcoming investor conferences:
    Jefferies Biotech on the Bay Summit, March 12-13th: Alto management will participate in one-on-one meetings with investors during the conference.
  • UBS Virtual CNS Day, March 18th: Amit Etkin, M.D., Ph.D., founder and chief executive officer, will participate in a fireside chat on Monday, March 18, 2024, at 2:30 pm ET.
  • Stifel 2024 Virtual CNS Days, March 19-20th: Dr. Etkin will participate in a fireside chat on Wednesday, March 20, 2024, at 11:30 am ET.
  • Alto management will also participate in one-on-one meetings with investors during the conference.

Pioneering work in computational and theoretical neuroscience is awarded the world’s largest brain research prize

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Technology, Other Health, Health, General Health, Health Technology, Other Science, Medical Devices, Research, Software, Science, Nervous system, Multimedia, AI, Neuroscience, Courage, Intelligence, Brain, Neuron, Schizophrenia, Language, Harvard University, Mathematics, Learning, Perception, Physics, Computation, Foundationalism, Memory, The Brain Prize, Cognition, Epilepsy, Knowledge, Imagination, Columbia University, Hebrew University of Jerusalem, Pharmaceutical industry

The Lundbeck Foundation has announced the recipients of The Brain Prize 2024, the world’s largest award for outstanding contributions to neuroscience.

Key Points: 
  • The Lundbeck Foundation has announced the recipients of The Brain Prize 2024, the world’s largest award for outstanding contributions to neuroscience.
  • View the full release here: https://www.businesswire.com/news/home/20240305504553/en/
    Theoretical and computational neuroscience permeates neuroscience today and is of increasingly growing importance.
  • The Brain Prize 2024 worth DKK 10 million (€1.3 million) is awarded to:
    Larry Abbott (USA), Terrence Sejnowski (USA), and Haim Sompolinsky (Israel/USA) for their Foundational work in Computational and Theoretical Neuroscience.
  • Chair of The Brain Prize Selection Committee, Professor Richard Morris, explains the reasoning behind this year’s award:
    “It is inconceivable to imagine modern brain sciences without the concomitant development of computational and theoretical neuroscience.

Microsoft and 1910 Genetics Partner to Build the Infrastructure Layer for Drug Discovery and Development Using AI and High-Performance Computing

Retrieved on: 
Thursday, February 29, 2024
Research, General Health, Pharmaceutical, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Other Technology, Other Science, Health, Therapy, HPC, Doctor of Philosophy, Multimedia, Artificial intelligence, Chemistry, AI, Neuroscience, Drug development, Drug discovery, Government, Playground Global, Learning, Observation, AQE, Automation, Infection, Potential, Corporation, Microsoft, Robotics, Observational comedy, Lithium, Cancer, Partnership, Pharmaceutical industry

1910 will offer the platform to pharmaceutical, biotechnology, government, academic, and research institutions via three partnership models: Co-discovery, Co-engineering, and Platform-as-a-Service.

Key Points: 
  • 1910 will offer the platform to pharmaceutical, biotechnology, government, academic, and research institutions via three partnership models: Co-discovery, Co-engineering, and Platform-as-a-Service.
  • “We are thrilled to be collaborating with 1910 Genetics to bring their pioneering AI drug discovery engines to Azure Quantum Elements,” said Jason Zander, Executive Vice President of Strategic Missions and Technologies at Microsoft.
  • Our collaboration with 1910 Genetics demonstrates our shared commitment to innovation and our aspiration to solve some of the most challenging problems the world faces in drug discovery.
  • AI offers an unprecedented opportunity to compress these cycles, accelerate the time from observation to discovery, and reduce the need for experimentation.

Oticon Names Winners of the 25th Annual Oticon Focus on People Awards

Retrieved on: 
Thursday, February 29, 2024
Children, FDA, Other Health, Health, Women, Seniors, Men, Medical Devices, Family, Consumer, Teens, Marketing, Hearing, Seton Hall University, African Americans, Doctor of Philosophy, Neuroscience, Education, Hearing loss, Nose, Dream, Quality of life, University, Empowerment, Centre for Social Justice, Conference, Social justice, Long-term care, Disability, Kool-Aid, Sign language, Trailblazer, Employment, Doctor of Audiology, Literature, Brain, Student, Dentistry

Oticon, Inc. announced the winners of the Oticon Focus on People Awards , a national awards program celebrating outstanding advocates, hearing care professionals and everyday heroes who make a positive impact on the hearing loss community.

Key Points: 
  • Oticon, Inc. announced the winners of the Oticon Focus on People Awards , a national awards program celebrating outstanding advocates, hearing care professionals and everyday heroes who make a positive impact on the hearing loss community.
  • As a high school senior, he founded 3 Tiny Bones, a nonprofit focused on destigmatizing hearing loss and educating people on healthy hearing.
  • In addition, eligible first-place winners with hearing loss in the Student Standouts, Adult Trailblazers and Hearing Loss Champions categories received a pair of Oticon hearing aids.
  • Established in 1997, the Oticon Focus on People Awards program has honored more than 300 outstanding individuals throughout the United States.

Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model

Retrieved on: 
Wednesday, February 28, 2024
Research, Neurology, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Acquisition, Neuropharmacology, Morris water navigation task, Dementia, Neuroscience, MWM, Amnesia, IGC, Spatial navigation, Deficit spending, Peptide, Memory, Spatial memory, Patient, LTP, Agitation, Mouse

The data demonstrated enhanced memory function in an Alzheimer's mouse model, including improved memory acquisition, consolidation, and retrieval.

Key Points: 
  • The data demonstrated enhanced memory function in an Alzheimer's mouse model, including improved memory acquisition, consolidation, and retrieval.
  • Ram Mukunda, CEO, commented, "These results underscore the efficacy of TGR-63 in enhancing spatial memory function in an Alzheimer's disease model, offering promising implications for potential therapeutic interventions in Alzheimer's and related neurodegenerative conditions.
  • The improvements in memory acquisition, consolidation, spatial memory formation, and retrieval highlight its potential in addressing cognitive impairment in Alzheimer's Disease.
  • The NOR Test, a cornerstone of preclinical research, evaluates recognition memory, a component of declarative memory responsible for recognizing previously encountered stimuli.